This article presents a clinical approach to patchy, non-scarring hair loss and includes conditions like alopecia areata, trichotillomania, dermatophyte infection of the scalp, syphilitic alopecia and traction folliculitis.
Introduction
Shedding of hair is termed effluvium or defluvium, and the resulting condition is called alopecia (Greek: alópekia, [baldness]). The normal scalp is adorned with approximately 100 000 hairs. More than 90% are in the growing phase (anagen). Up to 100 hairs may normally be shed per day. Individuals are often aware of and very concerned about subtle thinning of their hair. Patients presenting with hair loss are commonly encountered in clinical practice. The causes of hair loss are outlined in Table I .
Differences between scarring and nonscarring hair loss are summarised in Table II . Five conditions frequently encountered in clinics and presenting with patchy, non-scarring hair loss, are alopecia areata, trichotillomania, dermatophyte infection of the scalp, secondary syphilis, and traction folliculitis/alopecia.
Alopecia areata
Alopecia areata (AA) is an autoimmune disease caused by interaction of T-lymphocytes and follicular epithelium resulting in progressive shrinkage of follicles and loss of hair. In case of fulminant AA, persons may experience "going grey overnight". Alopecia occurs in round or oval areas without any visible inflammation of the skin (Figure 1 ). There may be one, or several, discrete or confluent patches. Follicular openings are present. No atrophy or scarring occurs. The most common presenting area is the scalp, but the eyebrows, eyelashes, pubic hair and beard may also be involved. Alopecia areata totalis (AAT) refers to total absence of terminal scalp hair ( Figure 2 ) and alopecia areata universalis (AAU) to total loss of terminal body and scalp hair. Ophiasis is characterised by a bandlike pat- 
Differential diagnosis
In the differential diagnosis, secondary syphilis, grey-patch tinea capitis, trichotillomania, traction alopecia, early chronic cutaneous lupus erythematosus and androgenetic alopecia should be considered. The differences between trichotillomania and alopecia areata are outlined in Table III .
Course
Spontaneous remission is common in patchy AA. Poor prognosis is associated with a number of factors (Table  IV) . If AA occurs after puberty, 80% of patients experience hair regrowth within a year. Recurrences of AA are, however, frequent. 
Management
No cure is currently available. Remission may be induced but the course is not altered. Treatment for AA is generally unsatisfactory. In many cases, the most important factor in the management of the patient is psychological support from the dermatologist, family, and support groups. Individuals may prefer to wear a wig. Make-up applied to the eyebrows is helpful. The first line of treatment is the application of a potent steroid cream twice daily for six weeks. If there is no improvement, this treatment should be terminated. Few and small spots of AA can be treated with an intralesional steroid. Tufted regrowth of hair commonly results.
Systemic glucocorticoids usually induce regrowth, but AA recurs on discontinuation. The risks of long-term therapy therefore rule out their use. Systemic cyclosporin induces regrowth, but AA recurs when the drug is discontinued. Cyclosporin is costly and renal damage is troublesome. Induction of allergic contact dermatitis with nitrochlorobenzene, squaric acid dibutylester, or diphencyprone can be used successfully, but local discomfort due to allergic contact dermatitis, and the swelling of regional lymph nodes, poses a problem. Oral PUVA (photochemotherapy) is variably effective, as high as 30%, and worth a trial in patients who are very distressed by the problem. The entire body must be exposed since the therapy is believed to be a form of systemic immune suppression. PUVA treatment has many side effects, the most important being nausea, photosensitivity and the development of nonmelanoma skin cancer.
Trichotillomania
Trichotillomania (TTM), first described by Halopeau in 1889, is an obsessivecompulsive disorder, characterised by the irresistible urge to pull out hair. There is a sensation of relief after the pulling episodes. The psychological stimulus is satisfied by hair plucking, but the resulting unsightly alopecia fuels the anxiety of the patient and results in a vicious cycle.
Adult TTM is more frequently chronic and is associated with more profound psychopathy. Adult TTM is more common in females (females:males 15:1). Childhood TTM is more common and also more common in females (females: males 4:1). TTM usually involves the 
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scalp, but sometimes the eyebrows or eyelashes are plucked. Manual dominance is characteristic: left-sided lesions develop in right-handed patients and vice versa. Lesions are ill-defined and the scalp surface is normal (Figure 3 ). The stubble of unevenly broken hairs is highly characteristic. The residual stubble hair has a normal colour and texture. Sometimes dystrophic "exclamation hairs" may also be found in TTM.
The differences between AA and TTM are outlined in Table III .
Dermatophyte infection of the scalp
Tinea capitis is most commonly caused by Trichophyton violaceum of the species trichophyton. The infection is usually spread from person to person. Infection by species of the genus microsporum is less common. Microsporum infection is usually acquired from cats or dogs.
The clinical presentation of this dermatophyte infection is variable, the commonest being grey-patch tinea capitis. The number of lesions is variable. A single lesion may be present, but more commonly one finds several lesions. Lesions show loss of hair and greyish, tightly packed, small scales ( Figure 4 ). diculosis should always be borne in mind.
The diagnosis of tinea capitis can often be established clinically, and can be confirmed by microscopy of skin scrapings or hair plucked from involved areas. Such samples can also be despatched for culture on Sabouraud's dextrose agar. A therapeutic trial of antifungal treatment remains an acceptable alternative.
The treatment of choice is griseofulvin 10 -20 mg/kg per day, with a meal, for 6 to 8 weeks. Patients should be followed up to ensure adequate healing of the infection. Regular use of a shampoo containing povidone-iodine decreases the shedding of spores.
Syphilitic alopecia (Secondary syphilis)
Secondary syphilis, the stage of spirochaetemia, is characterised by constitutional symptoms, variable organ involvement, generalised lymphadeno-pathy, skin eruptions, mucosal lesions, mucocutaneous lesions and hair loss. Skin eruptions include macular, papular, papulosquamous, nodular and pustular variants. The skin rash is usually asymptomatic and symmetrical. The palms and soles are commonly involved. In late stage secondary syphilis, lesions often show an arciform, annular or cory- Yellow-patch tinea capitis is a related condition. Lesions are covered with yellowish crusts caused by secondary pyoderma. Tinea capitis may also be seborrhoeic dermatitis-like and pustular. Black-dot tinea capitis is characterised by patches of alopecia studded with black dots which represent brokenoff hair shafts packed with spores. Abscess-like lesions, e.g. kerion, and lesions displaying saucer-shaped scales (= scutulae) e.g. favus, are infrequent. Secondary pyoderma and cervical lymphadenopathy are often present. Pyoderma may lead to scarring ( Figure  5 ). When pyoderma of the scalp is observed, tinea capitis, scabies and pe- imbiform pattern. Snail track ulcers are commonly observed on the oral mucosa and flat, glistening condylomata lata are present at moist mucocutaneous junctions. Syphilitic alopecia is characterised by patches of hair loss on the scalp. These patches show normal skin. The pattern is typically described as moth-eaten ( Figure 6 ). No particular pattern is observed. A clinical diagnosis of secondary syphilis is confirmed by appropriate serological tests. A skin biopsy may be helpful. Treatment with penicillin is usually curative.
Traction folliculitis/alopecia
Hair and scalp diseases induced by traumatic hairstyling techniques, such as tightly drawn braids (Figure 7 ), are underappreciated. A geometric pattern with the hair sectioned into squares or bands is highly characteristic. The hair in each square or band is pulled tightly to the centre and then secured with a hair band. Maximum traction is produced round the outer edges of the square or band with less traction in the centre. The first noticeable changes are faint erythema, some scaling and follicular mini pustules. Subsequently, in the areas of maximum traction, follicle-based papules and pustules associated with alopecia become evident. Hair loss and follicle-based papules and pustules along the frontal scalp margin are common. Previous trials in type 2 diabetic patients clearly demonstrated the benefit of lowering blood pressure in these patients. However, the Blood Pressure target of 130/89 mmHg was never reached in these trials, and blood pressure treatment seen as intensive was in fact not intensive by today's standards. Therefore, the blood pressure lowering arm of ADVANCE, with the use of Coversyl Plus ® (perindopril 4mg and indapamide 1,25mg), aimed to begin lowering BP where previous trials have ended by including type 2 diabetic patients whatever their Blood Pressure level (average starting blood pressure 145/81). These patients were included in order to demonstrate the benefit of blood pressure lowering, as opposed to only treating hypertension. Coversyl Plus ® was chosen specifically for AD-VANCE, since perindopril has demonstrated 24 hour blood pressure control, and both perindopril and indapamide are glucose and lipid neutral. Added to this is the evidence that perindopril has proven benefits beyond blood pressure lowering.
In ADVANCE, Coversyl Plus ® was added to all existing therapy including antihypertensives, lipid-lowering therapy and antiplatelet therapy.
For the physician, ADVANCE will show whether additional blood pressure lowering with Coversyl Plus ® , will reduce mortality and the risk of the type 2 diabetic developing macro -and microvascular complications. These results should ensure that blood pressure lowering in this patient group, with an appropriately selected combination of agents, gets the attention that it deserves.
FOR MORE INFORMATION AND RE-SULTS VISIT: www.advance-trial.com
